Bio Key International INC 8-K filings

BIO-key International held its annual meeting on August 22, 2024, where stockholders elected directors, ratified the auditor, and approved executive compensation matters.

BIO-key International reported a reduced net loss and improved cash flow from operations in Q2 2024, despite a decrease in revenue due to delayed software license recognition and lower project-related services revenue.

BIO-key International has entered into a note purchase agreement, securing $2 million in net proceeds for general working capital through a senior secured promissory note.

BIO-key International announced its Q1 2024 results, showing stable revenue year-over-year, a significant increase in gross profit, and positive operating cash flow.

BIO-key International has received a notice from Nasdaq regarding its failure to meet the minimum stockholders' equity requirement for continued listing.

BIO-key International has received a second notice from Nasdaq for failing to file its quarterly report, adding to previous concerns about its annual report, and faces a potential delisting if it does not submit a compliance plan.

BIO-key International has changed its independent registered public accounting firm from Marcum LLP to Bush & Associates, effective April 23, 2024.

BIO-key International received a non-compliance notice from Nasdaq for failing to file its annual report on time and will restate previous financial statements due to accounting errors.

BIO-key International announced preliminary 2023 results, showing a significant reduction in operating loss and a 29% increase in revenue.

BIO-key International has successfully regained compliance with Nasdaq's minimum bid price requirement after its stock price remained above $1.00 for ten consecutive business days.